



**BlueCross BlueShield
of Oklahoma**

If a conflict arises between a Clinical Payment and Coding Policy (“CPCP”) and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. “Plan documents” include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. BCBSOK may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSOK has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act (“HIPAA”) approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing (“UB”) Editor, American Medical Association (“AMA”), Current Procedural Terminology (“CPT”), CPT® Assistant, Healthcare Common Procedure Coding System (“HCPCS”), ICD-10 CM and PCS, National Drug Codes (“NDC”), Diagnosis Related Group (“DRG”) guidelines, Centers for Medicare and Medicaid Services (“CMS”) National Correct Coding Initiative (“NCCI”) Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Coronavirus Testing in the Outpatient Setting

Policy Number: CPCPLAB057

Version 1.0

Enterprise Clinical Payment and Coding Policy Committee Approval Date:

Plan Effective Date: March 1, 2024

Description

BCBSOK has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

NOTE 1: Antibody testing for the SARS-CoV-2 (COVID-19) virus provided under an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) during a public health emergency

is **NOT** addressed by this policy.

1. Targeted nucleic acid testing, such as RT-PCR, for COVID-19 (SARS-CoV-2) including rapid molecular tests **may be reimbursable** in the following situations:
 - a. For individuals displaying signs and symptoms of possible COVID-19 infection (See **NOTE 2**).
 - b. For asymptomatic individuals with known exposure to COVID-19, EXCEPT when the individual has had a previous COVID-19 infection within the last 90 days.
 - c. For asymptomatic individuals prior to undergoing immunosuppressive or aerosol-producing procedures.
2. For individuals with signs or symptoms of severe acute respiratory syndrome (SARS) who have traveled to endemic areas or who have been exposed to persons with SARS, targeted nucleic acid testing, such as RT-PCR for the detection of SARS coronavirus RNA, **may be reimbursable**.
3. For individuals with signs and symptoms of Middle East respiratory syndrome (MERS) who have traveled to endemic areas or who have been exposed to persons with MERS, targeted nucleic acid testing, such as RT-PCR for the detection of MERS coronavirus RNA **may be reimbursable**.
4. Host antibody serology testing to support a diagnosis of multisystem inflammatory syndrome in children (MIS-C) (see **Note 3**) multisystem inflammatory syndrome in adults (MIS-A) (see **Note 4**) or post-acute sequelae of SARS-CoV-2 infection (PASC) **may be reimbursable**.
5. For symptomatic individuals, the use of an antigen-detecting diagnostic test, for SARS-CoV-2 including antigen rapid tests, **may be reimbursable**.
6. For individuals with signs and symptoms of a respiratory tract infection (see **Note 5**) multiplex PCR-based panel testing of up to **5** respiratory pathogens **may be reimbursable**.
7. For individuals with signs and symptoms of a respiratory tract infection (see **Note 5**) antigen panel testing of up to **5** antigens **may be reimbursable**.
8. For the diagnosis of SARS-CoV-2 reinfection, whole genome sequencing of paired specimens from distinct lineages (as defined in Nextstrain or GISAID) **is not reimbursable**.
9. Antigen panel testing of **6** or more antigens **is not reimbursable**.
10. Multiplex PCR-based panel testing of **6 or more** respiratory pathogens **is not reimbursable**.
11. For all other situations not described above, host antibody serology testing **is not reimbursable**.
12. For all situations, neutralization antibody testing for SARS-CoV-2 **is not reimbursable**.
13. Testing for other endemic coronaviruses, such as 229E, NL63, OC43, and HKU1, **is not reimbursable**.

NOTE 2 Signs and symptoms associated with a possible COVID-19 infection can include a fever, cough, fatigue, shortness of breath or difficulty breathing, congestion or runny nose, chills, muscle pain, sore throat, new loss of taste or smell, nausea, vomiting, diarrhea, conjunctivitis, rash on skin or discoloration of fingers or toes (CDC, 2020f; WHO, 2020d).

Note 3: According to the CDC, evidence of possible MIS-C includes (CDC, 2021d):

- Fever of at least 38.0°C for at least 24 hours
- Multisystem (2 or more) organ involvement
- Laboratory evidence of inflammation, “including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), , or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin (CDC, 2020d)”
- Some children may fulfill full or partial criteria for Kawasaki disease

Note 4: According to the CDC, evidence of possible MIS-A includes (Morris et al., 2020; Patel et al., 2021):

- A severe illness requiring hospitalization in a person aged ≥21 years;
- A positive test result for current or previous SARS-CoV-2 infection (nucleic acid, antigen, or antibody) during admission or in the previous 12 weeks;
- Severe dysfunction of one or more extrapulmonary organ systems (e.g., hypotension or shock, cardiac dysfunction, arterial or venous thrombosis or thromboembolism, or acute liver injury);
- Laboratory evidence of severe inflammation (e.g., elevated CRP, ferritin, D-dimer, or interleukin-6);
- Absence of severe respiratory illness (to exclude patients in which inflammation and organ dysfunction might be attributable simply to tissue hypoxia).

Note 5: Signs and symptoms of a respiratory tract infection:

- A temperature greater than 102° F
- Pronounced dyspnea
- Tachypnea, or
- Tachycardia.

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Codes
86318, 86328, 86408, 86409, 86413, 86769, 86790, 87426, 87428, 87631, 87632, 87633, 87635, 87797, 87798, 87799, 87811, 0115U, 0202U, 0223U, 0224U, 0225U, 0226U, 0408U, C9803, G2023, G2024, U0001, U0002, U0003, U0004, U0005

References:

AAP. (2022a, September 7). *COVID-19 Testing Guidance*. <https://services.aap.org/en/pages/2019-novel->

[coronavirus-covid-19-infections/clinical-guidance/covid-19-testing-guidance/](https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-testing-guidance/)

AAP. (2022b, June 10). *Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance* <https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/>

AMA. (2020, 05/14/2020). *Serological testing for SARS-CoV-2 antibodies*. American Medical Association. Retrieved 05/19/2020 from <https://www.ama-assn.org/delivering-care/public-health/serological-testing-sars-cov-2-antibodies>

ASM. (2021, July 23). *How Dangerous is the Delta Variant (B.1.617.2)?* <https://asm.org/Articles/2021/July/How-Dangerous-is-the-Delta-Variant-B-1-617-2>

AstraZeneca. (2021, January 29). *COVID-19 Vaccine AstraZeneca recommended for use in the EU*. Retrieved January 30 from <https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-recommended-for-use-in-the-eu.html>

Backer, J. A., Klinkenberg, D., & Wallinga, J. (2020). Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. *Euro Surveill*, 25(5). <https://doi.org/10.2807/1560-7917.Es.2020.25.5.2000062>

Baum, S. G. (2020). Adult Multisystem Inflammatory Syndrome Associated with COVID-19. *NEJM*. <https://www.jwatch.org/na52622/2020/10/21/adult-multisystem-inflammatory-syndrome-associated-with>

BD_Veritor. (2020). *Veritor™ System* <https://www.fda.gov/media/139755/download>

Bezerra, M. F., Machado, L. C., De Carvalho, V., Docena, C., Brandão-Filho, S. P., Ayres, C. F. J., Paiva, M. H. S., & Wallau, G. L. (2021). A Sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern. *Infect Genet Evol*, 92, 104910. <https://doi.org/10.1016/j.meegid.2021.104910>

BioFire. (2020, 05/2020). *BioFire® Respiratory Panel 2.1 (RP2.1)*. FDA. Retrieved 05/04/2020 from <https://www.fda.gov/media/137583/download>

BioGerm. (2020). 2019-nCoV nucleic acid detection kit. http://www.bio-germ.com/zt.php?class_id=102

BioSpace. (2020, 8/20/20). *Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs*.

BodiTechMed. (2020). AFIAS COVID-19 Ab. http://www.boditech.co.kr/eng/board/news/board_view.asp?num=30109

Branswell, H. (2020, December 19). *A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines*. Retrieved January 30 from <https://www.statnews.com/2020/12/19/a-side-by-side-comparison-of-the-pfizer-biontech-and-moderna-vaccines/>

Caturegli, G., Materi, J., Howard, B. M., & Caturegli, P. (2020). Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study. *Ann Intern Med*, 173(8), 614-622. <https://doi.org/10.7326/m20-2889>

CDC. (2016, February 11). *What is whole genome sequencing (WGS)?*
<https://www.cdc.gov/pulsenet/pathogens/wgs.html>

CDC. (2020a, 03/15/2020). *CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel*
FDA. Retrieved 04/30/2020 from <https://www.fda.gov/media/134922/download>

CDC. (2020b, 02/15/2020). *Human Coronavirus Types*. CDC. Retrieved 05/15/2020 from
<https://www.cdc.gov/coronavirus/types.html>

CDC. (2020c, 7/2/2020). *Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay*.
<https://www.fda.gov/media/139744/download>

CDC. (2020d, 05/14/2020). *Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with
Coronavirus Disease 2019 (COVID-19)*. CDC. Retrieved 05/26/2020 from
<https://emergency.cdc.gov/han/2020/han00432.asp>

CDC. (2020e, 06/06/2020). *Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR
Primer and Probe Information*. Centers for Disease Control and Prevention. Retrieved 08/21/20 from
<https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>

CDC. (2020f, 12/22/20). *Symptoms of Coronavirus*. Retrieved 2/11/21 from
<https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>

CDC. (2021a, March 8). *Guidance for Businesses and Employers: Plan, Prepare, and Respond to
Coronavirus Disease 2019*. Centers for Disease Control and Prevention. Retrieved 8/21/20 from
<https://www.cdc.gov/coronavirus/2019-ncov/community/guidance-business-response.html>

CDC. (2021b, October 7). *Interim Guidance for SARS-CoV-2 Testing in Non-Healthcare Workplaces*.
[https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/testing-non-healthcare-
workplaces.html](https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/testing-non-healthcare-workplaces.html)

CDC. (2021c, May 11). *Johnson & Johnson's Janssen COVID-19 Vaccine*.
<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html>

CDC. (2021d, 5/20/21). *Multisystem Inflammatory Syndrome*. CDC. Retrieved 04/19/2022 from
<https://www.cdc.gov/mis/mis-c/hcp/index.html>

CDC. (2022a, September 28). *COVID-19 Testing: What You Need To Know*.
<https://www.cdc.gov/coronavirus/2019-ncov/testing/serology-overview.html>

CDC. (2022b). *COVID-19 Vaccine Booster Shots*. [https://www.cdc.gov/coronavirus/2019-
ncov/vaccines/booster-shot.html?s_cid=11706:cdc%20covid%20booster:sem.ga:p:RG:GM:gen:PTN:FY22](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html?s_cid=11706:cdc%20covid%20booster:sem.ga:p:RG:GM:gen:PTN:FY22)

CDC. (2022c, November 11). *COVID Data Tracker Variant Proportions*. [https://covid.cdc.gov/covid-data-
tracker/#variant-proportions](https://covid.cdc.gov/covid-data-tracker/#variant-proportions)

CDC. (2022d, March 30, 2022). *Different COVID-19 Vaccines*. Retrieved April 19 from
<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim->

considerations-us.html

CDC. (2022e, September 14). *Ending Isolation and Precautions for People with COVID-19: Interim Guidance*. CDC. Retrieved 08/18/2020 from <https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html>

CDC. (2022f). Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm7106a4.htm?s_cid=mm7106a4_w

CDC. (2022g, July 15). *Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing*. <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html>

CDC. (2022h, Jan. 24, 2022). *Interim Guidelines for COVID-19 Antibody Testing*. Retrieved 04/20/2022 from <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html>

CDC. (2022i, January 24). *Interim Guidelines for COVID-19 Antibody Testing*. <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html>

CDC. (2022j, August 11). *Isolations and Precautions for People with COVID-19*. <https://www.cdc.gov/coronavirus/2019-ncov/your-health/isolation.html>

CDC. (2022k). *Omicron Variant: What you need to know*. CDC. Retrieved April 19, 2022 from <https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html>

CDC. (2022l). *Omicron Variant: What You Need to Know*. <https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html>

CDC. (2022m, September 22). *Post-COVID Conditions: Information for Healthcare Providers*. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html>

CDC. (2022n, September 28). *Testing for SARS-CoV-2 (COVID-19) Overview*. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html>

CDC. (2022o). *Understanding How COVID-19 Vaccines Work*. Retrieved April 19, 2022 from <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html>

CDC. (2022p). *Variant Proportions*. <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>

CDC. (2022q, March 2022). *Viral Vector Vaccines*. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.html>

CDC. (2022r, February 5). *What You Need to Know about Variants*. Retrieved April 19, 2022 from <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html>

CDC, & OSHA. (2021, June 11). *Meat and Poultry Processing Workers and Employers: Interim Guidance from CDC and the Occupational Safety and Health Administration (OSHA)*. Retrieved 08/18/2020 from <https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/meat-poultry-processing-workers-employers.html>

Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J., & Ho, A. (2021). SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *The Lancet Microbe*, 2(1), E13-E22. [https://doi.org/10.1016/S2666-5247\(20\)30172-5](https://doi.org/10.1016/S2666-5247(20)30172-5)

Chan, J. F., Yip, C. C., To, K. K., Tang, T. H., Wong, S. C., Leung, K. H., Fung, A. Y., Ng, A. C., Zou, Z., Tsoi, H. W., Choi, G. K., Tam, A. R., Cheng, V. C., Chan, K. H., Tsang, O. T., & Yuen, K. Y. (2020). Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/HeI Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens. *J Clin Microbiol*, 58(5). <https://doi.org/10.1128/jcm.00310-20>

Chau, N. V. V., Hong, N. T. T., Ngoc, N. M., Anh, N. T., Trieu, H. T., Nhu, L. N. T., Yen, L. M., Minh, N. N. Q., Phong, N. T., Truong, N. T., Huong, L. T. T., Tu, T. N. H., Hung, L. M., Thanh, T. T., Dung, N. T., Dung, N. T., Thwaites, G., Van Tan, L., & for, O. C.-r. g. (2021). Rapid whole-genome sequencing to inform COVID-19 outbreak response in Vietnam. *The Journal of infection*, 82(6), 276-316. <https://doi.org/10.1016/j.jinf.2021.03.017>

Churiwal, M., Lin, K. D., Khan, S., Chhetri, S., Muller, M. S., Tompkins, K., Smith, J., Litel, C., Whittelsey, M., Basham, C., Rapp, T., Cerami, C., Premkumar, L., & Lin, J. T. (2021). Assessment of the Field Utility of a Rapid Point-of-Care Test for SARS-CoV-2 Antibodies in a Household Cohort. *Am J Trop Med Hyg*, 106(1), 156-159. <https://doi.org/10.4269/ajtmh.21-0592>

CMS. (2021, October 21). *Frequently Asked Questions: SARS-CoV-2 Surveillance Testing*. Retrieved 8/19/20 from <https://www.cms.gov/files/document/06-19-2020-frequently-asked-questions-covid-surveillance-testing.pdf>

Corman, V. M., Lienau, J., & Witzenthath, M. (2019). [Coronaviruses as the cause of respiratory infections]. *Internist (Berl)*, 60(11), 1136-1145. <https://doi.org/10.1007/s00108-019-00671-5> (Coronaviren als Ursache respiratorischer Infektionen.)

Cucinotta, D., & Vanelli, M. (2020). WHO Declares COVID-19 a Pandemic. *Acta Biomed*, 91(1), 157-160. <https://doi.org/10.23750/abm.v91i1.9397>

Dao Thi, V. L., Herbst, K., Boerner, K., Meurer, M., Kremer, L. P. M., Kirrmaier, D., Freistaedter, A., Papagiannidis, D., Galmozzi, C., Stanifer, M. L., Boulant, S., Klein, S., Chlanda, P., Khalid, D., Barreto Miranda, I., Schnitzler, P., Kräusslich, H.-G., Knop, M., & Anders, S. (2020). A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Science Translational Medicine*, 12(556), eabc7075. <https://doi.org/10.1126/scitranslmed.abc7075>

DeBiasi, R. L., Song, X., Delaney, M., Bell, M., Smith, K., Pershad, J., Anusinha, E., Hahn, A., Hamdy, R., Harik, N., Hanisch, B., Jantusch, B., Koay, A., Steinhorn, R., Newman, K., & Wessel, D. (2020). Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region. *J Pediatr*. <https://doi.org/10.1016/j.jpeds.2020.05.007>

Diao, B., Wen, K., Chen, J., Liu, Y., Yuan, Z., Han, C., Chen, J., Pan, Y., Chen, L., Dan, Y., Wang, J., Chen, Y., Deng, G., Zhou, H., & Wu, Y. (2020). Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein. *medRxiv*, 2020.2003.2007.20032524. <https://doi.org/10.1101/2020.03.07.20032524>

Dighe, K., Moitra, P., Alafeef, M., Gunaseelan, N., & Pan, D. (2022). A rapid RNA extraction-free lateral flow assay for molecular point-of-care detection of SARS-CoV-2 augmented by chemical probes. *Biosensors and Bioelectronics*, 200, 113900. <https://doi.org/https://doi.org/10.1016/j.bios.2021.113900>

ECDC. (2020, September 18). *Testing strategies for SARS-CoV-2*. <https://www.ecdc.europa.eu/en/covid-19/surveillance/testing-strategies>

ECDC. (2021, May 3). *Guidance for representative and targeted genomic SARS-CoV-2 monitoring*. <https://www.ecdc.europa.eu/en/publications-data/guidance-representative-and-targeted-genomic-sars-cov-2-monitoring>

ECDC. (2022, August 15). *Diagnostic testing and screening for SARS-CoV-2*. European Centre for Disease Prevention and Control. Retrieved 04/18/2022 from <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/diagnostic-testing>

EpitopeDiagnostics. (2020). EDI™ Novel Coronavirus COVID-19 ELISA Kits. <http://www.epitopediagnostics.com/covid-19-elisa>

Espejo, A. P., Akgun, Y., Al Mana, A. F., Tjendra, Y., Millan, N. C., Gomez-Fernandez, C., & Cray, C. (2020). Review of Current Advances in Serologic Testing for COVID-19. *Am J Clin Pathol*, 154(3), 293-304. <https://doi.org/10.1093/ajcp/aqaa112>

FDA. (2020a). ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY SARS-CoV-2 RT-PCR Assay. <https://www.fda.gov/media/141192/download>

FDA. (2020b, 7/9/2020). *CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay*. <https://www.fda.gov/media/139743/download>

FDA. (2020c). *Coronavirus (COVID-19) Update: FDA Issues First Emergency Authorization for Sample Pooling in Diagnostic Testing*. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-first-emergency-authorization-sample-pooling-diagnostic>

FDA. (2021a, May 11). *Coronavirus (COVID-19) Update: 10/15/21*. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-101521>

FDA. (2021b, April 22). *Illumina COVIDSeq Test*. <https://www.fda.gov/media/138778/download>

FDA. (2022a, 02/24/2022). *Antibody (Serology) Testing for COVID-19: Information for Patients and Consumers*. <https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/antibody-serology-testing-covid-19-information-patients-and-consumers>

FDA. (2022b). *Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples*. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-diagnostic-test-using-breath-samples>

FDA. (2022c, 04/14/2022). *Emergency Use Authorization*. Retrieved 04/20/2022 from <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy->

[framework/emergency-use-authorization](#)

FDA. (2022d, January 29). *In Vitro Diagnostics EUAs*. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas>

FDA. (2022e). *Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)*.
FDA. Retrieved 04/20/2022 from <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised>

GenMark_Diagnostics. (2020). ePlex Respiratory Pathogen Panel 2.
<https://www.fda.gov/media/142902/download>

Griffin, D. (2020, December 31). *Viral Load as a Predictor of COVID-19 Patient Outcomes*.
<https://www.cuimc.columbia.edu/news/viral-load-predictor-covid-19-patient-outcomes>

Guo, L., Ren, L., Yang, S., Xiao, M., Chang, D., Yang, F., Dela Cruz, C. S., Wang, Y., Wu, C., Xiao, Y., Zhang, L., Han, L., Dang, S., Xu, Y., Yang, Q.-W., Xu, S.-Y., Zhu, H.-D., Xu, Y.-C., Jin, Q., . . . Wang, J. (2020). Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaa310>

GVN. (2021, <https://gvn.org/covid-19/delta-b-1-617-2/>). *Delta Variant (B.1.617.2)*.

Helix. (2020, 8/6/20). *Helix COVID-19 NGS Test*. Retrieved 8/20/20 from
<https://www.fda.gov/media/140917/download>

Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Ferris, A., Kernan, K. F., Schulert, G. S., Seo, P., MB, F. S., Tremoulet, A. H., Yeung, R. S. M., Mudano, A. S., Turner, A. S., Karp, D. R., & Mehta, J. J. (2020). American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. *Arthritis Rheumatol*. <https://doi.org/10.1002/art.41454>

Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Ferris, A., Kernan, K. F., Schulert, G. S., Seo, P., Son, M. B. F., Tremoulet, A. H., Yeung, R. S. M., Mudano, A. S., Turner, A. S., Karp, D. R., & Mehta, J. J. (2020). American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 2. *Arthritis Rheumatol*.
<https://doi.org/10.1002/art.41616>

Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Kernan, K. F., Schulert, G. S., Seo, P., Son, M. B. F., Tremoulet, A. H., VanderPluym, C., Yeung, R. S. M., Mudano, A. S., Turner, A. S., Karp, D. R., & Mehta, J. J. (2022). American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. *Arthritis & Rheumatology*, 74(4), e1-e20.
<https://doi.org/https://doi.org/10.1002/art.42062>

Hirotsu, Y., Maejima, M., Shibusawa, M., Nagakubo, Y., Hosaka, K., Amemiya, K., Sueki, H., Hayakawa, M., Mochizuki, H., Tsutsui, T., Kakizaki, Y., Miyashita, Y., Yagi, S., Kojima, S., & Omata, M. (2020). Comparison of Automated SARS-CoV-2 Antigen Test for COVID-19 Infection with Quantitative RT-PCR using 313 Nasopharyngeal Swabs Including from 7 Serially Followed Patients. *Int J Infect Dis*.

<https://doi.org/10.1016/j.ijid.2020.08.029>

Hogan, C. A., Sahoo, M. K., & Pinsky, B. A. (2020). Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2. *Jama*, 323(19), 1967-1969. <https://doi.org/10.1001/jama.2020.5445>

Hulick, P. (2020, August 21). *Next-generation DNA sequencing (NGS): Principles and clinical applications*. <https://www.uptodate.com/contents/next-generation-dna-sequencing-ngs-principles-and-clinical-applications>

IDSA. (2020a, December 23). *IDSA Algorithm for SARS-CoV-2 Nucleic Acid Testing*. IDSA. Retrieved 05/13/2020 from <https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/diagnostics/figure-01.png>

IDSA. (2020b, December 23). *Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing*. IDSA. Retrieved 05/13/2020 from <https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/>

IDSA. (2020c, August 18). *Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing*. <https://www.idsociety.org/practice-guideline/covid-19-guideline-serology/>

JHU. (2022, November 11). *COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)*. Johns Hopkins University. <https://coronavirus.jhu.edu/map.html>

Jones, V. G., Mills, M., Suarez, D., Hogan, C. A., Yeh, D., Bradley Segal, J., Nguyen, E. L., Barsh, G. R., Maskatia, S., & Mathew, R. (2020). COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. *Hosp Pediatr*. <https://doi.org/10.1542/hpeds.2020-0123>

Kawasuji, H., Takegoshi, Y., Kaneda, M., Ueno, A., Miyajima, Y., Kawago, K., Fukui, Y., Yoshida, Y., Kimura, M., Yamada, H., Sakamaki, I., Tani, H., Morinaga, Y., & Yamamoto, Y. (2020). Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. *PLOS ONE*, 15(12), e0243597. <https://doi.org/10.1371/journal.pone.0243597>

Ko, J. H., Joo, E. J., Park, S. J., Baek, J. Y., Kim, W. D., Jee, J., Kim, C. J., Jeong, C., Kim, Y. J., Shon, H. J., Kang, E. S., Choi, Y. K., & Peck, K. R. (2020). Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients. *J Clin Med*, 9(7). <https://doi.org/10.3390/jcm9072268>

Kontou, P. I., Braliou, G. G., Dimou, N. L., Nikolopoulos, G., & Bagos, P. G. (2020). Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. *Diagnostics (Basel)*, 10(5). <https://doi.org/10.3390/diagnostics10050319>

Kweon, O. J., Lim, Y. K., Kim, H. R., Kim, M. C., Choi, S. H., Chung, J. W., & Lee, M. K. (2020). Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays. *PLOS ONE*, 15(10), e0240395. <https://doi.org/10.1371/journal.pone.0240395>

LabCorp. (2020a, 3/16/20). *ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY*. Retrieved 8/21/20 from <https://www.fda.gov/media/136151/download>

LabCorp. (2020b, 04/20/2020). *ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY COVID-19 RT-PCR TEST (LABORATORY CORPORATION OF AMERICA)*. FDA. Retrieved 04/26/2020 from <https://www.fda.gov/media/136151/download>

Lambert-Niclot, S., Cuffel, A., Le Pape, S., Vauloup-Fellous, C., Morand-Joubert, L., Roque-Afonso, A. M., Le Goff, J., & Delaugerre, C. (2020). Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. *J Clin Microbiol*, 58(8). <https://doi.org/10.1128/jcm.00977-20>

Li, M., Wei, R., Yang, Y., He, T., Shen, Y., Qi, T., Han, T., Song, Z., Zhu, Z., Ma, X., Lin, Y., Yuan, Y., Zhao, K., Lu, H., & Zhou, X. (2021). Comparing SARS-CoV-2 Testing in Anterior Nasal Vestibular Swabs vs. Oropharyngeal Swabs. *Front Cell Infect Microbiol*, 11, 653794. <https://doi.org/10.3389/fcimb.2021.653794>

Li, Y., Yao, L., Li, J., Chen, L., Song, Y., Cai, Z., & Yang, C. (2020). Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. *Journal of medical virology*, 92(7), 903-908. <https://doi.org/10.1002/jmv.25786>

Lippi, G., Simundic, A. M., & Plebani, M. (2020). Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin Chem Lab Med*. <https://doi.org/10.1515/cclm-2020-0285>

Lisboa Bastos, M., Tavaziva, G., Abidi, S. K., Campbell, J. R., Haraoui, L. P., Johnston, J. C., Lan, Z., Law, S., MacLean, E., Trajman, A., Menzies, D., Benedetti, A., & Ahmad Khan, F. (2020). Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *Bmj*, 370, m2516. <https://doi.org/10.1136/bmj.m2516>

Loeffelholz, M. J., & Tang, Y.-W. (2020). Laboratory diagnosis of emerging human coronavirus infections – the state of the art. *Emerging Microbes & Infections*, 9(1), 747-756. <https://doi.org/10.1080/22221751.2020.1745095>

Lu, Y., Li, L., Ren, S., Liu, X., Zhang, L., Li, W., & Yu, H. (2020). Comparison of the diagnostic efficacy between two PCR test kits for SARS-CoV-2 nucleic acid detection. *Journal of Clinical Laboratory Analysis*, 34(10), e23554. <https://doi.org/10.1002/jcla.23554>

Ludwig, S., & Zarbock, A. (2020). Coronaviruses and SARS-CoV-2: A Brief Overview. *Anesth Analg*. <https://doi.org/10.1213/ane.0000000000004845>

LumiraDx. (2020). *SARS-CoV-2 Ag Test*. <https://www.fda.gov/media/141304/download>

Mak, G. C., Cheng, P. K., Lau, S. S., Wong, K. K., Lau, C. S., Lam, E. T., Chan, R. C., & Tsang, D. N. (2020). Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *J Clin Virol*, 129, 104500. <https://doi.org/10.1016/j.jcv.2020.104500>

Mandavilli, A. (2021, July 30). *C.D.C. Internal Report Calls Delta Variant as Contagious as Chickenpox*. <https://www.nytimes.com/2021/07/30/health/covid-cdc-delta-masks.html>

Mathieu, E., Ritchie, H., Rodés-Guirao, L., Appel, C., Giattino, C., Hasell, J., Macdonald, B., Dattani, S.,

Beltekian, D., Ortiz-Ospina, E., & Roser, M. (2022, November 11). *Coronavirus (COVID-19) Vaccinations*. <https://ourworldindata.org/covid-vaccinations?country=USA>

Mawhorter, M. E., Nguyen, P., Goldsmith, M., Owens, R. G., Baer, B., & Raman, J. D. (2022). Diagnostic yield and costs associated with a routine pre-operative COVID-19 testing algorithm for asymptomatic patients prior to elective surgery. *Am J Clin Exp Urol*, *10*(5), 341-344.

Mboumba Bouassa, R.-S., Tonen-Wolyec, S., Veyer, D., Péré, H., & Bélec, L. (2022). Analytical performances of the AMPLIQUICK® Respiratory Triplex assay for simultaneous detection and differentiation of SARS-CoV-2, influenza A/B and respiratory syncytial viruses in respiratory specimens. *PLOS ONE*, *17*(1), e0262258. Retrieved 2022, from

McIntosh, K. (2021, April 2). *COVID-19: Clinical features*. Wolter Kluwer. Retrieved 08/19/2020 from <https://www.uptodate.com/contents/covid-19-clinical-features>

Miller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gilligan, P. H., Gonzalez, M. D., Jerris, R. C., Kehl, S. C., Patel, R., Pritt, B. S., Richter, S. S., Robinson-Dunn, B., Schwartzman, J. D., Snyder, J. W., Telford, S., 3rd, Theel, E. S., Thomson, R. B., Jr., Weinstein, M. P., & Yao, J. D. (2018). A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. *Clin Infect Dis*, *67*(6), e1-e94. <https://doi.org/10.1093/cid/ciy381>

Morell, A., Skvaril, F., Nosedá, G., & Barandun, S. (1973). Metabolic properties of human IgA subclasses. *Clinical and experimental immunology*, *13*(4), 521-528. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553728/>

Morris, S. B., Schwartz, N. G., Patel, P., Abbo, L., Beauchamps, L., Balan, S., Lee, E. H., Paneth-Pollak, R., Geevarughese, A., Lash, M. K., Dorsinville, M. S., Ballen, V., Eiras, D. P., Newton-Cheh, C., Smith, E., Robinson, S., Stogsdill, P., Lim, S., Fox, S. E., . . . Godfred-Cato, S. (2020). Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020. *MMWR Morb Mortal Wkly Rep*, *69*(40), 1450-1456. <https://doi.org/10.15585/mmwr.mm6940e1>

Nackerdien, Z. (2020, December 6). *Viral Load Peaks in First Week of COVID-19 Symptom Onset*. Retrieved January 31 from <https://www.medpagetoday.com/infectiousdisease/covid19/90035>
Nagura-Ikeda, M., Imai, K., Tabata, S., Miyoshi, K., Murahara, N., Mizuno, T., Horiuchi, M., Kato, K., Imoto, Y., Iwata, M., Mimura, S., Ito, T., Tamura, K., & Kato, Y. (2020). Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19. *J Clin Microbiol*. <https://doi.org/10.1128/jcm.01438-20>

NIH. (2020, December 28). *Phase 3 trial of Novavax investigational COVID-19 vaccine opens*. Retrieved January 30 from <https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens>

NIH. (2022a, September 26). *Clinical Spectrum of SARS-CoV-2 Infection*. National Institutes of Health. <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>

NIH. (2022b, August 8). *Testing for SARS-CoV-2 Infection*. National Institutes of

Health. <https://www.covid19treatmentguidelines.nih.gov/overview/sars-cov-2-testing/>

Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., Yazdanpanah, Y., Le Hingrat, Q., Descamps, D., Houhou-Fidouh, N., Reusken, C., Bosch, B. J., Drosten, C., Koopmans, M. P. G., & Haagmans, B. L. (2020). Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerg Infect Dis*, 26(7). <https://doi.org/10.3201/eid2607.200841>

OSHA. (2020). *Guidance on Preparing Workplaces for COVID-19*. Occupational Safety and Health Administration. Retrieved 04/29/2020 from <https://www.osha.gov/Publications/OSHA3990.pdf>

OSHA. (2021, June 10). *Protecting Workers: Guidance on Mitigating and Preventing the Spread of COVID-19 in the Workplace*. <https://www.osha.gov/coronavirus/safework#workers-who-have-had-covid-19>

Oude Munnink, B. B., Nieuwenhuijse, D. F., Stein, M., O'Toole, Á., Haverkate, M., Mollers, M., Kanga, S. K., Schapendonk, C., Pronk, M., Lexmond, P., van der Linden, A., Bestebroer, T., Chestakova, I., Overmars, R. J., van Nieuwkoop, S., Molenkamp, R., van der Eijk, A. A., GeurtsvanKessel, C., Vennema, H., . . . The Dutch-Covid-19 response, t. (2020). Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands. *Nature Medicine*, 26(9), 1405-1410. <https://doi.org/10.1038/s41591-020-0997-y>

Padoan, A., Cosma, C., Sciacovelli, L., Faggian, D., & Plebani, M. (2020). Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. *Clin Chem Lab Med*. <https://doi.org/10.1515/cclm-2020-0443>

Palavecino, E. (2015). *One Sample, Multiple Results The Use of Multiplex PCR for Diagnosis of Infectious Syndromes*. Retrieved 11/1 from <https://www.aacc.org/publications/cln/articles/2015/april/one-sample-multiple-results>

Patel, P., DeCuir, J., Abrams, J., Campbell, A. P., Godfred-Cato, S., & Belay, E. D. (2021). Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review. *JAMA Network Open*, 4(9), e2126456-e2126456. <https://doi.org/10.1001/jamanetworkopen.2021.26456>

Peacock, W. F., Soto-Ruiz, K. M., House, S. L., Cannon, C. M., Headden, G., Tiffany, B., Motov, S., Merchant-Borna, K., Chang, A. M., Pearson, C., Patterson, B. W., Jones, A. E., Miller, J., Varon, J., Bastani, A., Clark, C., Rafique, Z., Kea, B., Eppensteiner, J., . . . Young, S. (2022). Utility of COVID-19 antigen testing in the emergency department. *Journal of the American College of Emergency Physicians Open*, 3(1), e12605. <https://doi.org/https://doi.org/10.1002/emp2.12605>

Pfefferle, S., Reucher, S., Nörz, D., & Lütgehetmann, M. (2020). Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system. *Euro Surveill*, 25(9). <https://doi.org/10.2807/1560-7917.Es.2020.25.9.2000152>

Poljak, M., Korva, M., Gašper, N. K., Komloš, K. F., Sagadin, M., Uršič, T., Županc, T. A., Petrovec, M., & McAdam, A. J. (2020). Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic. *Journal of Clinical Microbiology*, 58(6), e00599-00520. <https://doi.org/doi:10.1128/JCM.00599-20>

Poplar. (2020). *EMERGENCY USE AUTHORIZATION (EUA) SUMMARY OF THE POPLAR SARS-COV-2 TMA POOLING ASSAY*. <https://www.fda.gov/media/140792/download>

Qiagen_GmbH. (2020, 03/2020). *QIAstat-Dx® Respiratory SARS-CoV2 Panel Instructions for Use (Handbook)*. FDA. Retrieved 04/27/2020 from <https://www.fda.gov/media/136571/download>

Quidel_Corporation. (2020, 05/2020). *Sofia 2 SARS Antigen FIA*. FDA. Retrieved 05/12/2020 from <https://www.fda.gov/media/137885/download>

Roberts, M. (2021, January 29). *Covid-19: Novavax shows 89% efficacy in UK trials*. Retrieved January 30 from <https://www.bbc.com/news/uk-55850352>

Ryding, S. (2020, June 24). *What is Viral Load?* Retrieved January 31 from <https://www.news-medical.net/health/What-is-Viral-Load.aspx>

SansureBiotech. (2020, 05-04-2020). *Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing)*. <https://www.fda.gov/media/137651/download>

Scohy, A., Anantharajah, A., Bodéus, M., Kabamba-Mukadi, B., Verroken, A., & Rodriguez-Villalobos, H. (2020). Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *J Clin Virol*, 129, 104455. <https://doi.org/10.1016/j.jcv.2020.104455>

Seo, G., Lee, G., Kim, M. J., Baek, S. H., Choi, M., Ku, K. B., Lee, C. S., Jun, S., Park, D., Kim, H. G., Kim, S. J., Lee, J. O., Kim, B. T., Park, E. C., & Kim, S. I. (2020). Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor. *ACS Nano*, 14(4), 5135-5142. <https://doi.org/10.1021/acsnano.0c02823>

Sri Santosh, T., Parmar, R., Anand, H., Srikanth, K., & Saritha, M. (2020). A Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19. *Cureus*, 12(4), e7708. <https://doi.org/10.7759/cureus.7708>

Taylor, J., Carter, R. J., Lehnertz, N., Kazazian, L., Sullivan, M., Wang, X., Garfin, J., Diekman, S., Plumb, M., Bennet, M. E., Hale, T., Vallabhaneni, S., Namugenyi, S., Carpenter, D., Turner-Harper, D., Booth, M., Coursey, E. J., Martin, K., McMahon, M., . . . Lynfield, R. (2020). Serial Testing for SARS-CoV-2 and Virus Whole Genome Sequencing Inform Infection Risk at Two Skilled Nursing Facilities with COVID-19 Outbreaks - Minnesota, April-June 2020. *MMWR Morb Mortal Wkly Rep*, 69(37), 1288-1295. <https://doi.org/10.15585/mmwr.mm6937a3>

The_Native_Antigen_Company. (2020, 03/24/2020). *Why We Need Antigen and Antibody Tests for COVID-19*. The Native Antigen Company. Retrieved 04/21/2020 from <https://thenativeantigencompany.com/why-we-need-antigen-and-antibody-tests-for-covid-19/>

To, K. K. W., Yip, C. C. Y., Lai, C. Y. W., Wong, C. K. H., Ho, D. T. Y., Pang, P. K. P., Ng, A. C. K., Leung, K. H., Poon, R. W. S., Chan, K. H., Cheng, V. C. C., Hung, I. F. N., & Yuen, K. Y. (2019). Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. *Clin Microbiol Infect*, 25(3), 372-378. <https://doi.org/10.1016/j.cmi.2018.06.009>

Tregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N. M., Pierce, B. F.,

Stirling, D. C., Wang, Z., & Pollock, K. M. (2020). Vaccines for COVID-19. *Clinical and experimental immunology*, 202(2), 162-192. <https://doi.org/10.1111/cei.13517>

UCSD. (2020). *UCSD RC SARS-CoV-2 Assay* <https://www.fda.gov/media/140712/download>

US. (2020, 03/27/2020). *H.R. 748 - CARES Act*. Retrieved 05/19/2020 from <https://www.congress.gov/116/bills/hr748/BILLS-116hr748enr.pdf>

Van Beusekom, M. (2020, December 8). *Phase 3 trials show AstraZeneca COVID vaccine has up to 90% efficacy*. University of Minnesota. Retrieved January 30 from <https://www.cidrap.umn.edu/news-perspective/2020/12/phase-3-trials-show-astrazeneca-covid-vaccine-has-90-efficacy>

Verdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri, M., Ciuffreda, M., Bonanomi, E., & D'Antiga, L. (2020). An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet*. [https://doi.org/10.1016/s0140-6736\(20\)31103-x](https://doi.org/10.1016/s0140-6736(20)31103-x)

Villaverde, S., Domínguez-Rodríguez, S., Sabrido, G., Pérez-Jorge, C., Plata, M., Romero, M. P., Grasa, C. D., Jiménez, A. B., Heras, E., Broncano, A., Núñez, M. D. M., Illán, M., Merino, P., Soto, B., Molina-Arana, D., Bermejo, A., Mendoza, P., Gijón, M., Pérez-Moneo, B., . . . Epidemiological Study of, C.-i. C. o. t. S. S. o. P. W. G. (2021). Diagnostic Accuracy of the Panbio Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Rapid Test Compared with Reverse-Transcriptase Polymerase Chain Reaction Testing of Nasopharyngeal Samples in the Pediatric Population. *The Journal of pediatrics*, 232, 287-289.e284. <https://doi.org/10.1016/j.jpeds.2021.01.027>

Wang, F., Huang, S., Gao, R., Zhou, Y., Lai, C., Li, Z., Xian, W., Qian, X., Li, Z., Huang, Y., Tang, Q., Liu, P., Chen, R., Liu, R., Li, X., Tong, X., Zhou, X., Bai, Y., Duan, G., . . . Liu, L. (2020). Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. *Cell Discovery*, 6(1), 83. <https://doi.org/10.1038/s41421-020-00231-4>

Wang, R., Qian, C., Pang, Y., Li, M., Yang, Y., Ma, H., Zhao, M., Qian, F., Yu, H., Liu, Z., Ni, T., Zheng, Y., & Wang, Y. (2020). opvCRISPR: One-pot visual RT-LAMP-CRISPR platform for SARS-cov-2 detection. *Biosensors and Bioelectronics*, 172, 112766. <https://doi.org/https://doi.org/10.1016/j.bios.2020.112766>

WHO. (2020a, 09/11/20). *Diagnostic testing for SARS-CoV-2*. Retrieved 11/08/20 from <https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2>

WHO. (2020b, 04/24/2020). *"Immunity passports" in the context of COVID-19*. World Health Organization. Retrieved 04/25/2020 from <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19>

WHO. (2020c, 05/15/2020). *Multisystem inflammatory syndrome in children and adolescents with COVID-19*. World Health Organization. Retrieved 05/18/2020 from <https://www.who.int/publications-detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>

WHO. (2020d, 04/17/2020). *Q&A on coronaviruses (COVID-19): What are the symptoms of COVID-19?* Retrieved 05/20/2020 from <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses>

WHO. (2021a, October 6). *Antigen-detection in the diagnosis of SARS-CoV-2 infection*. World Health Organization. Retrieved 11/08/2020 from <https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays>

WHO. (2021b, November 2021). *COVID-19 Clinical management: living guidance*. World Health Organization. Retrieved April 19 from <https://apps.who.int/iris/bitstream/handle/10665/349321/WHO-2019-nCoV-clinical-2021.2-eng.pdf>

WHO. (2021c). COVID-19 natural immunity. file:///C:/Users/AHCS8330/Downloads/WHO-2019-nCoV-Sci-Brief-Natural-immunity-2021.1-eng.pdf

WHO. (2022a, November 11). *Coronavirus disease (COVID-19) Pandemic*. World Health Organization. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

WHO. (2022b, 2022). *Middle East respiratory syndrome coronavirus (MERS-CoV)*. World Health Organization. Retrieved 08/19/2020 from <https://www.who.int/emergencies/mers-cov/en/>

WHO. (2022c). *SARS (Severe Acute Respiratory Syndrome)*. World Health Organization. Retrieved 04/19/2022 from <https://www.who.int/ith/diseases/sars/en/>

Woof, J. M., & Kerr, M. A. (2006). The function of immunoglobulin A in immunity. *The Journal of Pathology*, 208(2), 270-282. <https://doi.org/10.1002/path.1877>

Wright, D., & CMS. (2021, March 16). *Nursing Home Reopening Recommendations for State and Local Officials*. CMS. Retrieved 05/20/2020 from <https://www.cms.gov/files/document/nursing-home-reopening-recommendations-state-and-local-officials.pdf>

Wu, F., Liu, M., Wang, A., Lu, L., Wang, Q., Gu, C., Chen, J., Wu, Y., Xia, S., Ling, Y., Zhang, Y., Xun, J., Zhang, R., Xie, Y., Jiang, S., Zhu, T., Lu, H., Wen, Y., & Huang, J. (2020). Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. *JAMA Intern Med*. <https://doi.org/10.1001/jamainternmed.2020.4616>

Wulff, N. H., Tzatzaris, M., & Young, P. J. (2012). Monte Carlo simulation of the Spearman-Kaerber TCID50. *J Clin Bioinforma*, 2(1), 5. <https://doi.org/10.1186/2043-9113-2-5>

Xiao, D. A. T., Gao, D. C., & Zhang, D. S. (2020). Profile of Specific Antibodies to SARS-CoV-2: The First Report. *J Infect*. <https://doi.org/10.1016/j.jinf.2020.03.012>

Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., & Shang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*, 8(5), 475-481. [https://doi.org/10.1016/s2213-2600\(20\)30079-5](https://doi.org/10.1016/s2213-2600(20)30079-5)

Yau, F., Ferreira, R., Kamali, R., Bird, P. W., Halliwell, R., Patel, H., Nicoara, D. C., Woltmann, G., & Tang, J. W. (2021). Clinical utility of a rapid 'on-demand' laboratory-based SARS-CoV-2 diagnostic testing service in an acute hospital setting admitting COVID-19 patients. *Clin Infect Pract*, 12, 100086. <https://doi.org/10.1016/j.clinpr.2021.100086>

Yelin, I., Aharony, N., Shaer Tamar, E., Argoetti, A., Messer, E., Berenbaum, D., Shafran, E., Kuzli, A.,

Gandali, N., Shkedi, O., Hashimshony, T., Mandel-Gutfreund, Y., Halberthal, M., Geffen, Y., Szwarcwort-Cohen, M., & Kishony, R. (2020). Evaluation of COVID-19 RT-qPCR test in multi-sample pools. *Clin Infect Dis*. <https://doi.org/10.1093/cid/ciaa531>

Zhang, Y. V., Wiencek, J., Meng, Q. H., Theel, E. S., Babic, N., Sepiashvili, L., Pecora, N. D., Slev, P., Cameron, A., Konforte, D., & the, A. C. S. T. T. F. (2021). AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 EUA and LDT Serologic Testing in Clinical Laboratories. *Clinical Chemistry*. <https://doi.org/10.1093/clinchem/hvab051>

Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., Qian, S., Hong, C., Wang, F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., . . . Zhang, Z. (2020). Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaa344>

Zimmer, C., Corum, J., Wee, S., & Kristoffersen, M. (2022, August 31). *Coronavirus Vaccine Tracker*. <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>

Policy Update History:

Effective Date	Summary of Change
03/01/2024	Added code 0408U. No other changes made.
11/01/2023	Document updated with literature review. Reimbursement information revised for clarity. References revised; some added, others removed.
11/1/2022	New policy